Fran Curtis is a five-time survivor of cancers survivor including breast, appendix and skin cancer, but she told CURE in a ...

Investigators evaluated stromal content in the tumor microenvironment as a marker for bladder cancer prognosis, including disease-free survival and overall survival.

Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, ...

Merck (MRK) stock is in focus as the company's Keytruda versions win FDA priority review for an expanded indication in ...

The trial, also referred to as KEYNOTE-905, met its primary end point of EFS, resulting in a 60% reduction in the risk of tumor recurrence, progression, or death of patients treated with neoadjuvant ...

Stage 2 ovarian cancer means the cancer is present in one or both ovaries and has spread to other pelvic tissues, such as the ...

Dr. Ignacio Duran titled his discussion of abstracts 2595MO, 2600MO, 2610MO: Bringing any clarity into the non-clear or ...

While Natera said it will seek FDA approval for Signatera based on data from IMvigor011, the readout from another ctDNA-guided de-escalation study was more nuanced.